Sugi Predict

Sugi Predict / Compounds / SCHEMBL4476871

SCHEMBL4476871

SCHEMBL4476871

NC(=O)c1c(N)sc(C(=O)c2cc(-c3ccccc3)no2)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ RET P07949 1/20 0.40
▸ NPC1 O15118 7/20 0.40
▸ LIMK1 P53667 3/20 0.40
▸ IKBKB O14920 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ BTK Q06187 1/20 0.40
▸ MAPT P10636 3/20 0.39
▸ GAA P10253 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824983 0.81 MAPT (0.41) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL3816591 0.81 LMNA (0.40) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4464972 0.80 MELK (0.42) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL3816399 0.77 CHEK1 (0.41) RETMAPTLMNA
SCHEMBL3985673 0.76 RAB9A (0.64) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4474610 0.76 USP30 (0.43) RAB9ASMN1; SMN2RETMAPTLMNA
SCHEMBL28091339 0.76 RAB9A (0.68) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4472754 0.75 KDM4E (0.41) RAB9ASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL4466084 0.73 USP30 (0.41) RAB9ASMN1; SMN2IKBKBMAPTLMNA
SCHEMBL3853232 0.73 MELK (0.39) RAB9ASMN1; SMN2KDM4EKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 — — US disclosed
US-20060041006-A1 PDE4B inhibitors and uses therefor PLEXXIKON, INC. 2006-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A RAB9A 1343/4885SMN1; SMN2 1379/4885KDM4E 1483/4885
US-20060041006-A1 PDE4B inhibitors and uses therefor PDE4B, PDE7B, PDE4A RAB9A 1343/4885SMN1; SMN2 1379/4885KDM4E 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.